免疫检查点抑制剂毒性预测生物标志物的研究进展

doi:10.3969/j.issn.1006-5725.2023.20.001

Abstract

Abstract:

In the era of cancer immunotherapy， with the release of more clinical trial results， the use of ICIs is more and more widely， but about 40% of these patients will experience irAEs， even some patients with fatal irAEs， early identification of irAEs can reduce irAEs related deaths and medical costs， and biomarkers are an important indicator of early identification of toxic reaction caused by ICIs. We review the latest progress in predicting biomarkers of irAEs， guiding the study of more convenient and fast predictors or predictive models through the combing of biomarkers， ultimately serving clinical work.

Key words: immune-checkpoint inhibitors, immune-related adverse events, predictive biomarkers

CLC Number:

R730.5

Jun DENG,Jun WANG,Chang′e GAO,Xiao CHEN,Mingxia. SHI. Research progress of predictive biomarkers for immune⁃related adverse events[J]. The Journal of Practical Medicine, 2023, 39(20): 2561-2565.

References 48

1	王燕，庞雅琪，许新华.PD-1/PD-L1基因多态性在非小细胞肺癌中的研究进展［J］.实用医学杂志，2022，38（12）：1470-1474.
2	MUSIC M， IAFOLLA M， SOOSAIPILLAI A，et al. Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry［J］. F1000Res，2020，9：337.
3	LES I， MARTÍNEZ M， NARRO A，et al. Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies［J］. Ann Med，2021，53 （1）：762-769.
4	DE MOEL E C， ROAEMAN E A， KAPITEIJN E H，et al. Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors［J］. Cancer Immunol Res，2019，7 （1）：6-11.
5	ALSERAWAN L， ANGUERA G， ZAMORA ATENZA C，et al. Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events［J］. Int J Mol Sci，2022，23 （20）：12641.
6	NAKAMURA Y， TANAKA R， MARUYAMA H，et al. Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies［J］. Jpn J Clin Oncol，2019，49 （5）：431-437.
7	SUAZO-ZEPEDA E， BOKERN M， VINKE P C，et al. Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer： a systematic review and meta-analysis［J］. Cancer Immunol Immunother，2021，70 （11）：3069-3080.
8	刘剑，李敏菁. 全身免疫炎症指数对非小细胞肺癌免疫检查点抑制剂疗效的预测价值［J］. 实用医学杂志，2022，38（7）：904-908.
9	SUBUDHI S K， APARICIO A， GAO J，et al. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities［J］. Proc Natl Acad Sci U S A，2016，113 （42）：11919-11924.
10	GRANITO A， MURATORI L， LALANNE C，et al. Hepatocellular carcinoma in viral and autoimmune liver diseases： Role of CD4⁺ CD25⁺ Foxp3⁺ regulatory T cells in the immune microenvironment［J］. World J Gastroenterol，2021，27 （22）：2994-3009.
11	ARASANZ H， BOCANEGRA A I， MORILLA I，et al. Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer［J］. Cancers （Basel），2022，14 （16）：3846.
12	MUIR C A， CLIFTON-BLIGH R J， LONG G V，et al. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment［J］. J Clin Endocrinol Metab，2021，106 （9）：e3704-e3713.
13	ISAWA T，TOI Y， SUGAWARA S，et al. Incidence， Clinical Characteristics， and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors［J］. Oncologist，2022，27 （5）：e410-e419.
14	GONG Z， WANG Y. Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis： A Clinical Review［J］. JCO Oncol Pract，2020，16 （8）：453-461.
15	HUSAIN B， KIRCHBERGER M C， ERDMANN M，et al. Inflammatory markers in autoimmunity induced by checkpoint inhibitors［J］. J Cancer Res Clin Oncol，2021，147 （6）：1623-1630.
16	SHIMOZAKI K， SUKAWA Y， SATO Y，et al. Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data［J］. Future Oncol，2021，17 （20）：2593-2603.
17	ZHAO L， LI Y， JIANG N，et al. Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors［J］. J Immunother，2022，45 （4）：210-216.
18	TANAKA R， OKIYAMA N， OKUNE M，et al. Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity［J］. J Dermatol Sci，2017，86 （1）：71-73.
19	CHEN A Y， WOLCHOK J D， BASS A R. TNF in the era of immune checkpoint inhibitors： friend or foe？［J］. Nat Rev Rheumatol，2021，17 （4）：213-223.
20	MONTFORT A， FILLERON T， VIRAZELS M，et al. Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma： First Results of a Phase Ib Clinical Trial［J］. Clin Cancer Res，2021，27 （4）：1037-1047.
21	KANG D H， PARK C K， CHUNG C，et al. Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors［J］. Immune Netw，2020，20 （3）：e27.
22	DIMITRIOU F， HOGAN S， MENZIES A M，et al. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy［J］. Eur J Cancer，2021，157：214-224.
23	HAILEMICHAEL Y， JOHNSON D H， ANDEL-WAHAB N，et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity［J］. Cancer Cell，2022，40 （5）：509-523.e6.
24	TARHINI A A， ZAHOOR H， LIN Y，et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma［J］. J Immunother Cancer，2015，3：39.
25	JOHNSON D， PATEL A B， UEMURA M I，et al. IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy［J］. Cancer Immunol Res，2019，7 （6）：860-865.
26	ESFAHANI K， MILLER W H. Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade［J］. N Engl J Med，2017，376 （20）：1989-1991.
27	KURIMOTO C， INABA H， ARIYASU H，et al. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors［J］. Cancer Sci，2020，111 （5）：1468-1477.
28	FRIEDRICH M， POHIN M， JACKSON M A，et al. IL-1-driven stromal-neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies［J］. Nat Med，2021，27 （11）：1970-1981.
29	ANDREWS M C， DUONG C P M， GOPALAKRISHNAN V，et al. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade［J］. Nat Med，2021，27 （8）：1432-1441.
30	THOMAS A S， MA W， WANG Y. Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors［J］. N Engl J Med，2021，384 （6）：581-583.
31	WANG H， ZHOU F， ZHAO C，et al. Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy［J］. Front Immunol，2022，13：840313.
32	FUJIMURA T， SATO Y， TANITA K，et al. Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab： a pilot study［J］. Oncotarget，2018，9 （21）：15542-15551.
33	BINS S， BASAK E A， El BOUAZZAOUI S，et al. Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients［J］. Br J Cancer，2018，118 （10）：1296-1301.
34	KOBAYASHI M， NUMAKURA K， HATAKEYAMA S，et al. Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism［J］. Genes （Basel），2022，13（7）：1204.
35	ABDEL-WAHAB N， DIAB A， YU R K，et al. Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors［J］. Cancer Immunol Immunother， 2021，70（7）：1939-1949.
36	WÖLFFER M， BATTKE F， SCHULZE M，et al. Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma［J］. Cancers （Basel），2022，14 （2）：302.
37	JIN Y， CHEN D L， WANG F，et al. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors［J］. Mol Cancer，2020，19 （1）：154.
38	FRIEDLANDER P， WOOD K， WASSMANN K，et al. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab［J］. J Immunother Cancer，2018，6 （1）：90.
39	FINKE D， HECKMANN M B， SALATZKI J，et al. Comparative Transcriptomics of Immune Checkpoint Inhibitor Myocarditis Identifies Guanylate Binding Protein 5 and 6 Dysregulation［J］. Cancers （Basel），2021，13（10）：2498.
40	SHI Y， SHEN M， ZHENG X，et al. ICPis-Induced Autoimmune Polyendocrine Syndrome Type 2： A Review of the Literature and a Protocol for Optimal Management［J］. J Clin Endocrinol Metab，2020，105 （12）：dgaa553.
41	DELIVANIS D A， GUSTAFSON M P， BORNSCLEGL S，et al. Pembrolizumab-Induced Thyroiditis： Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms［J］. J Clin Endocrinol Metab，2017，102（8）：2770-2780.
42	IAFOLLA M A J， YANG C， CHANDRAN V，et al. Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis［J］. JNCI Cancer Spectr，2020，5（1）：pkaa115.
43	MASTROIANNI J， STICKEL N， ANDRLOVA H，et al. miR-146a Controls Immune Response in the Melanoma Microenvironment［J］. Cancer Res，2019，79 （1）：183-195.
44	IVANOVA E， ASADULLINA D， RAKHIMOV R，et al. Exosomal miRNA-146a is downregulated in clear cell renal cell carcinoma patients with severe immune-related adverse events［J］. Noncoding RNA Res，2022，7 （3）：159-163.
45	PANTAZI D， TSELEPIS A D. Cardiovascular toxic effects of antitumor agents： Pathogenetic mechanisms［J］. Thromb Res，2022，213 ：S95-S102.
46	CHAU J， YADAW M， LIU B，et al. Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer［J］. BMC Cancer，2021，21 （1）：808.
47	BERNER F， BOMZE D， LICHTENSTEIGER C，et al. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade［J］. Sci Immunol，2022，7 （75）：eabn9644.
48	TAHIR S A， GAO J， MIURA Y，et al. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities［J］. Proc Natl Acad Sci U S A，2019，116 （44）：22246-22251.

[1]	Huinan ZHOU,Kewei QIN,Lijun. ZHOU. Current research status and clinical application progress of the immune checkpoint LAG⁃3 and its targeting drugs [J]. The Journal of Practical Medicine, 2024, 40(11): 1607-1612.
[2]	Xiaona MENG,Xu SUN,Huaimin LIU. Advances in the study of immune checkpoint inhibitors⁃related colitis [J]. The Journal of Practical Medicine, 2024, 40(9): 1314-1319.
[3]	Yuling LI,Jianlin YANG,Zhi CUI,Jing WANG,Yafeng LV,Chunyu. CAO. Effect of BMI-1 inhibitor PTC-596 on proliferation， cell cycle， and apoptosis of human breast cancer MCF-7cells [J]. The Journal of Practical Medicine, 2023, 39(18): 2317-2322.

Research progress of predictive biomarkers for immune⁃related adverse events

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 48

Related Articles 3

Recommended Articles

Metrics

Comments